BioSpace News Archive

Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, announced it will soon open a high speed multi-purpose fill finish line in its state-of-the-art commercial manufacturing facility located in San Diego, CA.

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced that management will present at the Jefferies Virtual Healthcare Conference at 2:30 PM ET on Tuesday, June 1, 2021.

Concord Medical Services Holdings Limited, a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centers in China, announced that as of May 25, 2021, it is late in filing its annual report on Form 20-F for the fiscal year ended December 31, 2020 with the Securities and Exchange Commission.

AnPac Bio-Medical Science Co., Ltd., a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced that on May 17, 2021, its board of directors approved the Company to establish a joint venture together with its founder and chairman, Dr. Chris Chang Yu, and certain other individuals to develop a new cancer treatment technology and associated products.

Xilio to evaluate XTX101, a tumor selective anti-CTLA-4 monoclonal antibody, in combination with KEYTRUDA® (pembrolizumab) as a treatment for patients with solid tumors

Boston Scientific Corporation announced it has completed CE Mark for the EXALT™ Model B Single-Use Bronchoscope, a single-use device designed for bedside procedures in the intensive care unit, operating room and bronchoscopy suite.

Newly formed publicly traded company NRx Pharmaceuticals, Inc. (NRx) to be traded under the ticker symbol “NRXP” on the Nasdaq Global Market

Cyclerion Therapeutics, Inc. announced that Company management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:00 p.m. ET.

TherapeuticsMD, Inc., an innovative, leading women’s healthcare company, announced that the Company submitted a supplemental New Drug Application for BIJUVA capsules, 0.5 mg/100 mg, to the U.S. Food and Drug Administration.

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced the completion of patient enrollment of its Phase 1 clinical trial of EYP-1901 as a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration.